The New York Times is executing a successful digital transformation, evidenced by revenue growth accelerating from 5.8% in 2024Q2 to 11.2% in 2026Q2 and gross margin expanding from 46.7% to 51.8% over the same period. The company's asset-light model generates ...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 11.2% in 2026Q2, while operating margin expanded from 8.1% in 2024Q1 to 15.5% in 2026Q2, reflecting strong operating leverage.
NYT is defined as a high-quality stock, with academic research showing such stocks outperform by 4-6% annually over long periods.
With a momentum score of 70/100, NYT's stock has been recognized by the market, and momentum tends to persist.
Bank of America highlights NYT's multi-product digital platform built around the All-Access subscription model.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $0.69+4.1% vs $0.66 | $762M+1.4% vs $752M |
Q2 2026 May 6, 2026 | $0.61+30.2% vs $0.47 | $712M+1.8% vs $700M |
Q1 2026 Feb 4, 2026 | $0.89+1.1% vs $0.88 | $802M+1.4% vs $791M |
Q4 2025 Nov 5, 2025 | $0.59+10.7% vs $0.53 | $701M+1.8% vs $688M |
Markets are rattled ahead of Wednesday's Fed decision, and Wall Street analysts are making bold moves on names like Eli Lilly, Etsy, Northrop Grumman, and Rivian. Find out which stocks got upgraded, downgraded, or newly covered before the opening bell.
Overall Survival (OS) historical-control data gains HMRA and EMA support for pending CMAA submissions Full alignment achieved on confirmatory Phase 3 trial design Complete CMAA submission expected in coming weeks New York, New York and Rockville, Maryland--(Newsfile Corp. - September 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has achieved full alignment with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) on its pending Conditional Marketing Authorisation Application (CMAA). MHRA agreed that the use of comparable historical control data – derived from a systematic evaluation of all suitable available peer-reviewed literature by independent biostatistics advisors presented in its most recent Scientific Advice Meeting (SAM) - was appropriate in the orphan indication Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma.
AMSTERDAM--(BUSINESS WIRE)--Tommy Hilfiger, which is part of PVH Corp. [NYSE: PVH], staged a personal New York celebration today, presenting Spring 2027 at The Plaza Hotel. The legendary address — where Tommy Hilfiger once lived with his family — became the ultimate backdrop for modern prep, as uptown tradition and downtown cool passed through the same revolving doors. “For 40 years, I've been inspired by the style of New Yorkers — how the people of the city take the classics and make them thei.
The U.S. Justice Department is investigating whether Nvidia tried to skirt antitrust scrutiny of the chipmaker's licensing deal last year with AI chip startup Groq, the New York Times reported on Wednesday, citing two people familiar with the matter.
Benchmark NYT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for The New York Times Company (NYT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $65.45 | $10.63B | 31.32 | 9.24% | 12.18% | 17.34% | 1.02% | |
| $5.96 | $876.77M | -33.11 | -5.79% | 4.11% | 49.68% | — | |
| $32.38 | $17.72B | 31.44 | 6.82% | 6.35% | 6.15% | — | |
| $7.35 | $44.83M | -1.20 | -8.02% | -1.84% | — | — | |
| $38.76 | $2.88B | -29.14 | -37.14% | 19.66% | 8.53% | — | |
| $58.20 | $2.14B | 50.61 | 3.54% | 48.57% | 34.27% | — |
The New York Times Company (NYT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
The New York Times Company (NYT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
May 6, 2026·SEC
Apr 23, 2026·SEC
Get notified when NYT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
The New York Times Company (NYT) stock FAQ — growth, dividends, profitability & financials explained
The New York Times Company (NYT) reported $2.98B in revenue for fiscal year 2025. This represents a 14% increase from $2.62B in 1996.
The New York Times Company (NYT) grew revenue by 9.2% over the past year. This is steady growth.
Yes, The New York Times Company (NYT) is profitable, generating $392.8M in net income for fiscal year 2025 (12.2% net margin).
Yes, The New York Times Company (NYT) pays a dividend with a yield of 1.02%. This makes it attractive for income-focused investors.
The New York Times Company (NYT) has a return on equity (ROE) of 17.3%. This is reasonable for most industries.
The New York Times Company (NYT) generated $704.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
